Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy (LC_Biomarker)

Se-Hoon Lee

Status

Enrolling

Conditions

Lung Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT03578185

Lung cancer Biomarker_2018

Details and patient eligibility

About

This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.

Full description

[Sample acquisition]

Informed consent is waived for those who agree to donate samples left over from other clinical trials or acquired for other purposes to be used for other research by the sign to master agreement in advance.
The study will be conducted based on the purposes indicated in the master agreement signed by tissue donator [Clinical data acquisition]
Baseline demographics: Sex, Birth date, expire date (last follow-up date for the survivals)
Lung cancer treatment history: diagnosed date, treatment history (surgery, radiation therapy, chemotherapy, immunotherapy treatment history, and responses), general performance, metastatic sites
Lung cancer histologic information: pathology, histologic subtype, EGFR mutation profile, ALK-rearrangement result

Enrollment

800 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: